









Markets
/
Stocks
/
nasdaq-vyne
/

Vyne Therapeutics Inc

VYNE

View Detailed Chart

0.353USD

0.0000.00%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

5.63MMarket Cap

LossP/E TTM



Vyne Therapeutics Inc

0.353

0.0000.00%

Overview Company Financials

Financials

Intraday

30m

Today

-3.47%

5 Days

-75.83%

1 Month

-75.24%

6 Months

-84.79%

Year to Date

-89.47%

1 Year

-80.39%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 4 analysts

BUY

Current Rating

4.375

Target Price

1139.73%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Vyne Therapeutics Inc

VYNE

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Strong sell

Sell(11)

Neutral(0)

Buy(0)

Indicators

Sell(5)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.235

Sell

RSI(14)

28.440

Sell

STOCH(KDJ)(9,3,3)

10.215

Sell

ATR(14)

0.208

High Vlolatility

CCI(14)

-160.147

Sell

Williams %R

98.996

Oversold

TRIX(12,20)

-0.797

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.801

Sell

MA10

1.059

Sell

MA20

1.187

Sell

MA50

1.132

Sell

MA100

1.356

Sell

MA200

2.036

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Ticker SymbolVYNE

CompanyVyne Therapeutics Inc

CEOMr. David Domzalski

Websitehttps://vynetherapeutics.com/